DAVENPORT & Co LLC lessened its holdings in shares of Allergan plc (NYSE:AGN) by 99.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,272 shares of the company’s stock after selling 152,778 shares during the period. DAVENPORT & Co LLC’s holdings in Allergan were worth $208,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Pacific Center for Financial Services lifted its position in shares of Allergan by 1.3% during the 2nd quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock worth $132,000 after purchasing an additional 7 shares during the last quarter. Quadrant Capital Group LLC lifted its position in shares of Allergan by 1.4% during the 2nd quarter. Quadrant Capital Group LLC now owns 1,201 shares of the company’s stock worth $235,000 after purchasing an additional 16 shares during the last quarter. Ropes Wealth Advisors LLC lifted its position in shares of Allergan by 5.2% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 605 shares of the company’s stock worth $147,000 after purchasing an additional 30 shares during the last quarter. Citizens Financial Group Inc RI lifted its position in shares of Allergan by 4.1% during the 2nd quarter. Citizens Financial Group Inc RI now owns 858 shares of the company’s stock worth $209,000 after purchasing an additional 34 shares during the last quarter. Finally, Raymond James Trust N.A. lifted its position in shares of Allergan by 0.4% during the 2nd quarter. Raymond James Trust N.A. now owns 8,904 shares of the company’s stock worth $2,164,000 after purchasing an additional 36 shares during the last quarter. 81.26% of the stock is owned by institutional investors and hedge funds.
In other news, insider William Meury sold 11,807 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $173.89, for a total value of $2,053,119.23. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Chris W. Bodine acquired 3,030 shares of the stock in a transaction dated Thursday, December 7th. The stock was bought at an average price of $164.77 per share, for a total transaction of $499,253.10. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 17,630 shares of company stock worth $2,890,057. Corporate insiders own 0.36% of the company’s stock.
Shares of Allergan plc (AGN) opened at $176.72 on Thursday. Allergan plc has a 12 month low of $160.07 and a 12 month high of $256.80. The firm has a market capitalization of $59,420.00, a P/E ratio of -7.82, a PEG ratio of 1.31 and a beta of 1.11. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.40.
Allergan (NYSE:AGN) last released its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share for the quarter, beating the consensus estimate of $4.06 by $0.09. Allergan had a positive return on equity of 8.00% and a negative net margin of 47.27%. The company had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.04 billion. During the same period in the prior year, the company posted $3.32 EPS. The company’s revenue was up 11.4% compared to the same quarter last year. sell-side analysts predict that Allergan plc will post 16.27 earnings per share for the current year.
Allergan announced that its board has authorized a stock repurchase plan on Monday, September 25th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 2.8% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s management believes its stock is undervalued.
TRADEMARK VIOLATION WARNING: This article was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3143678/allergan-plc-agn-shares-sold-by-davenport-co-llc.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.